MMVD is a leading cause of CHF in dogs worldwide. The QUEST trial laid the groundwork for improved health and quality of life for animals suffering from this disease, in its examination of treatment for the symptomatic stage of disease. It also set a new standard of international co-operation and scientific rigour in running clinical studies in dogs.
Results of that study, along with several recently published academic papers, point to the need to also evaluate the effects of pimobendan at the preclinical stage of MMVD. The EPIC trial consists of a respected team of independent researchers in a double-blind, randomized, placebo-controlled multi-centre clinical study. Investigators will determine if chronic oral administration of pimobendan in dogs with evidence of increased heart size secondary to preclinical MMVD can delay the onset of signs of CHF. Complete EPIC results will be published and distributed, regardless of the outcome.
Professor Adrian Boswood
Royal Veterinary College
Veterinary Clinical Sciences
Hatfield, Hertfordshire, UK
Does chronic oral administration of pimobendan in dogs with evidence of increased heart size secondary to preclinical MMVD delay the onset of signs of congestive heart failure?
EPIC results will be published and distributed regardless of the outcome, ultimately informing and helping veterinarians better manage preclinical heart disease.